4 results match your criteria: "San Giovanni Bosco Hospital and University of Turin[Affiliation]"
Development of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-D Report: Multicriteria Decision Analysis.
Arthritis Care Res (Hoboken)
December 2024
Hospital for Special Surgery, Weill Cornell Medicine, New York City, New York.
Article Synopsis
- The 2023 ACR/EULAR antiphospholipid syndrome (APS) classification criteria development used a four-phase methodology to identify high likelihood patients for research purposes.
- In the final phase, a multicriteria decision analysis (MCDA) helped rank the importance of candidate criteria based on evaluations from 192 real-world patients suspected of having APS.
- The consensus reached emphasized the need for separate clinical and laboratory scores for APS classification, aiming for greater specificity compared to existing systems that rely on a single score.
Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study.
Arthritis Rheumatol
February 2022
University of Florence, Florence, Italy.
Objective: Mepolizumab proved to be an efficacious treatment for eosinophilic granulomatosis with polyangiitis (EGPA) at a dose of 300 mg every 4 weeks in the randomized, controlled MIRRA trial. In a few recently reported studies, successful real-life experiences with the approved dose for treating severe eosinophilic asthma (100 mg every 4 weeks) were observed. We undertook this study to assess the effectiveness and safety of mepolizumab 100 mg every 4 weeks and 300 mg every 4 weeks in a large European EGPA cohort.
View Article and Find Full Text PDFRituximab in severe immunoglobulin-A vasculitis (Henoch-Schönlein) with aggressive nephritis.
Clin Exp Rheumatol
September 2020
CMID-Nephrology and Dialysis Unit, Center of Research of Rheumatologic, Nephrologic and Rare Diseases, and Coordinating Centre of the Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hospital and University of Turin, Italy.
Objectives: Immunoglobulin-A vasculitis (IgAV) is a systemic small-vessel vasculitis in which renal involvement indicates severity of illness, and chronic kidney disease represents the most serious long-term complication. No treatment at present is specifically recommended for IgAV. Recently, rituximab (RTX) has been shown to be effective in case series of adults with IgAV.
View Article and Find Full Text PDFLong term follow-up to evaluate the efficacy of miglustat treatment in Italian patients with Niemann-Pick disease type C.
Orphanet J Rare Dis
February 2015
Department of Translational Medicine-Section of Pediatrics, Federico II University, Naples, Italy.
Background: Twenty-five patients with Niemann Pick disease type C (age range: 7 months to 44 years) were enrolled in an Italian independent multicenter trial and treated with miglustat for periods from 48 to 96 months.
Methods: Based on the age at onset of neurological manifestations patients' phenotypes were classified as: adult (n = 6), juvenile (n = 9), late infantile (n = 6), early infantile (n = 2). Two patients had an exclusively visceral phenotype.